{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:07:44Z","timestamp":1791223664666,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008334","name":"stiftung oskar-helene-heim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helmholtz Zentrum M\u00fcnchen - Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt (GmbH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither evidence from prospective data nor a guideline recommendation, which drug should be preferred over the other. This study aimed to compare pirfenidone and nintedanib-treated patients regarding all-cause mortality, all-cause and respiratory-related hospitalizations, and overall as well as respiratory-related health care costs borne by the Statutory Health Insurance (SHI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study with SHI data was performed, including IPF patients treated either with pirfenidone or nintedanib. Stabilized inverse probability of treatment weighting (IPTW) based on propensity scores was applied to adjust for observed covariates. Weighted Cox models were estimated to analyze mortality and hospitalization. Weighted cost differences with bootstrapped 95% confidence intervals (CI) were applied for cost analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We compared 840 patients treated with pirfenidone and 713 patients treated with nintedanib. Both groups were similar regarding two-year all-cause mortality (HR: 0.90 95% CI: 0.76; 1.07), one-year all cause (HR: 1.09, 95% CI: 0.95; 1.25) and respiratory-related hospitalization (HR: 0.89, 95% CI: 0.72; 1.08). No significant differences were observed regarding total (\u20ac\u2212\u00a0807, 95% CI: \u20ac\u2212\u00a02977; \u20ac1220) and respiratory-related (\u20ac\u2212\u00a01282, 95% CI: \u20ac\u2212\u00a03423; \u20ac534) costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our analyses suggest that the patient-related outcomes mortality, hospitalization, and costs do not differ between the two currently available antifibrotic drugs pirfenidone and nintedanib. Hence, the decision on treatment with pirfenidone versus treatment with nintedanib ought to be made case-by-case taking clinical characteristics, comorbidities, comedications, individual risk of side effects, and patients\u2019 preferences into account.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-021-01857-y","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T17:20:34Z","timestamp":1634664034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-7296","authenticated-orcid":false,"given":"Pavo","family":"Marijic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Schwarzkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Schwettmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Trudzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"issue":"5","key":"1857_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1857_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001\u201311. Lancet Respir Med. 2014;2(7):566\u201372.","journal-title":"Lancet Respir Med"},{"issue":"22","key":"1857_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"22","key":"1857_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"1857_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","volume":"5","author":"SD Nathan","year":"2017","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33\u201341.","journal-title":"Lancet Respir Med"},{"key":"1857_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74\u20139.","journal-title":"Respir Med"},{"key":"1857_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02279-2019","author":"J Behr","year":"2020","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.02279-2019.","journal-title":"Eur Respir J"},{"issue":"6","key":"1857_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","volume":"196","author":"B Ley","year":"2017","unstructured":"Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"1857_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.049","author":"T Petnak","year":"2021","unstructured":"Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2021. https:\/\/doi.org\/10.1016\/j.chest.2021.06.049.","journal-title":"Chest"},{"issue":"19","key":"1857_CR10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811\u201323.","journal-title":"N Engl J Med"},{"key":"1857_CR11","doi-asserted-by":"publisher","first-page":"581828","DOI":"10.3389\/fmolb.2020.581828","volume":"7","author":"P Cameli","year":"2020","unstructured":"Cameli P, Refini RM, Bergantini L, d\u2019Alessandro M, Alonzi V, Magnoni C, et al. Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study. Front Mol Biosci. 2020;7:581828.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"1857_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","volume":"200","author":"TM Dempsey","year":"2019","unstructured":"Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1857_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12931-021-01714-y","volume":"22","author":"M Belhassen","year":"2021","unstructured":"Belhassen M, Dalon F, Nolin M, Van Ganse E. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):135.","journal-title":"Respir Res"},{"issue":"3","key":"1857_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pulmoe.2018.06.003","volume":"25","author":"E Bargagli","year":"2019","unstructured":"Bargagli E, Piccioli C, Rosi E, Torricelli E, Turi L, Piccioli E, et al. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Pulmonology. 2019;25(3):149\u201353.","journal-title":"Pulmonology"},{"issue":"13","key":"1857_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2217\/cer-2020-0084","volume":"9","author":"M Corral","year":"2020","unstructured":"Corral M, Chang E, Broder MS, Gokhale S, Reddy SR. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis. J Comp Eff Res. 2020;9(13):933\u201343.","journal-title":"J Comp Eff Res"},{"key":"1857_CR16","unstructured":"Bundesministerium f\u00fcr Gesundheit (BMG). Gesetzliche Krankenversicherung\u2014Mitglieder, mitversicherte Angeh\u00f6rige und Krankenstand \u2013 Monatswerte Jahresdurchschnitt 2018: BMG; 2019. https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_JD_2018.pdf. Accessed 20 June 2021."},{"issue":"10097","key":"1857_CR17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse R, Bl\u00fcmel M, Knieps F, B\u00e4rnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. The Lancet. 2017;390(10097):882\u201397.","journal-title":"The Lancet"},{"issue":"1","key":"1857_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-020-01335-x","volume":"21","author":"J Walscher","year":"2020","unstructured":"Walscher J, Witt S, Schwarzkopf L, Kreuter M. Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment\u2014a German claims data analysis. Respir Res. 2020;21(1):73.","journal-title":"Respir Res"},{"issue":"1","key":"1857_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"28","key":"1857_CR20","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"9","key":"1857_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/cer-2020-0013","volume":"9","author":"V Allan","year":"2020","unstructured":"Allan V, Ramagopalan SV, Mardekian J, Jenkins A, Li X, Pan X, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603\u201314.","journal-title":"J Comp Eff Res"},{"key":"1857_CR22","unstructured":"Federal Institute for Research on Building Urban Affairs and Spatial Development. Laufende Raumbeobachtung\u2014Raumabgrenzungen. 2021. https:\/\/www.bbsr.bund.de\/BBSR\/DE\/forschung\/raumbeobachtung\/Raumabgrenzungen\/deutschland\/kreise\/siedlungsstrukturelle-kreistypen\/kreistypen.html. Accessed 20 June 2021."},{"key":"1857_CR23","doi-asserted-by":"crossref","unstructured":"Maier W. Indizes multipler deprivation zur Analyse regionaler Gesundheitsunterschiede in Deutschland: Erfahrungen aus Epidemiologie und Versorgungsforschung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017;60(12):1455\u20136.","DOI":"10.1007\/s00103-017-2664-0"},{"key":"1857_CR24","doi-asserted-by":"crossref","unstructured":"Maier W, Fairburn J, Mielck A. Regionale Deprivation und Mortalitat in Bayern. Entwicklung eines \u201cIndex Multipler Deprivation\u201d auf Gemeindeebene. Gesundheitswesen. 2012;74(7):416\u201325.","DOI":"10.1055\/s-0031-1280846"},{"issue":"1","key":"1857_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"11","key":"1857_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"1","key":"1857_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-018-0769-0","volume":"19","author":"L Schwarzkopf","year":"2018","unstructured":"Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis. Respir Res. 2018;19(1):73.","journal-title":"Respir Res"},{"issue":"3","key":"1857_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"issue":"3","key":"1857_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.chest.2015.11.013","volume":"149","author":"WJ Canestaro","year":"2016","unstructured":"Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest. 2016;149(3):756\u201366.","journal-title":"Chest"},{"key":"1857_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-016-0558-x","volume":"14","author":"B Rochwerg","year":"2016","unstructured":"Rochwerg B, Neupane B, Zhang Y, Garcia CC, Raghu G, Richeldi L, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med. 2016;14:18.","journal-title":"BMC Med"},{"issue":"1","key":"1857_CR31","doi-asserted-by":"publisher","first-page":"15620","DOI":"10.1038\/s41598-020-72607-1","volume":"10","author":"J Kang","year":"2020","unstructured":"Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep. 2020;10(1):15620.","journal-title":"Sci Rep"},{"issue":"5","key":"1857_CR32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2213-2600(15)00093-4","volume":"3","author":"MT Durheim","year":"2015","unstructured":"Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015;3(5):388\u201396.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1857_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1378\/chest.13-2424","volume":"147","author":"AW Brown","year":"2015","unstructured":"Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147(1):173\u20139.","journal-title":"Chest"},{"issue":"1","key":"1857_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12890-020-01224-5","volume":"20","author":"M Corral","year":"2020","unstructured":"Corral M, DeYoung K, Kong AM. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study. BMC Pulm Med. 2020;20(1):188.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1857_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12931-020-1315-4","volume":"21","author":"CH Holtze","year":"2020","unstructured":"Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, et al. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respir Res. 2020;21(1):48.","journal-title":"Respir Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01857-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T17:21:04Z","timestamp":1634664064000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01857-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01857-y","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"15 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We performed a retrospective analysis of completely anonymized data. According to the German Guidelines for Secondary Data Analysis, ethical approval and consent to participate is not required for this type of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michael Kreuter received grants and fees for consultation and speeches from Galapagos, Boehringer Ingelheim, and Roche either for himself or his institution. Larissa Schwarzkopf received fees for consultation from Galapagos. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}